hVIVO plc Directors' Dealings (5119K)

TIDMHVO

RNS Number : 5119K

hVIVO plc

10 July 2017

For immediate release 7.00am: 10 July 2017

HVIVO PLC

("hVIVO" or the "Company")

Directors' Dealings

hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that application has been made to AIM for the admission of 21,363 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").

The New Ordinary Shares have been allotted pursuant to the purchase by Jaime Ellertson (Non-Executive Chairman) and Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of their letters of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Ellertson and Mr Winschel had entered into binding commitments to purchase $20,000 and GBP4,000 of hVIVO plc new ordinary shares respectively per quarter. On 7 June 2017, Jaime Ellertson volunteered to reduce his Director's fee by 10% to $180k pa, and his quarterly purchase of shares by 10% to $18,000, with effect from 1 June '17.

The New Ordinary Shares represent their investments for the quarter ended 30 June 2017. On 7 July 2017, Mr Ellertson invested in an additional 16,888 ordinary shares and Mr Winschel invested in an additional 4,475 ordinary shares, at a price of 89.4 pence per share.

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 78,150,671 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 13 July 2017. Following Admission, Mr Ellertson and Mr Winschel will be interested in a total of 94,550 and 44,790 ordinary shares of 5.0p in the Company respectively, each representing less than 0.1% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the persons discharging managerial 
       responsibilities/persons closely associated 
---  ------------------------------------------------------------ 
 a)   Name               Jaime Ellertson and Jim Winschel 
---  -----------------  ----------------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------ 
 a)   Position/          Non-Executive Chairman and Non-Executive 
       status             Director 
---  -----------------  ----------------------------------------- 
 b)   Initial            Initial Notification 
       notification/ 
       Amendment 
---  -----------------  ----------------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ------------------------------------------------------------ 
 a)   Name               hVIVO plc 
---  -----------------  ----------------------------------------- 
 b)   Legal Entity       N/A 
       Identifier 
---  -----------------  ----------------------------------------- 
 4    Details of the transaction(s): section 
       to be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ------------------------------------------------------------ 
 a)   Description        Ordinary shares of 5 pence each 
       of the 
       financial 
       instrument,        GB00B6ZM0X53 
       type of 
       instrument 
 
       Identification 
       code 
---  -----------------  ----------------------------------------- 
 b)   Nature             Acquisition of ordinary shares 
       of the 
       transaction 
---  -----------------  ----------------------------------------- 
 c)   Currency           GBP 
---  -----------------  ----------------------------------------- 
 d)   Price(s)             Director           Price (p)   Volume 
       and volume(s)      -----------------  ----------  ------- 
                           Jaime Ellertson    89.4        16,888 
                          -----------------  ----------  ------- 
                            Jim Winschel       89.4        4,475 
                          -----------------  ----------  ------- 
---  ----------------- 
 
 e)   Aggregated 
       information 
       - Aggregated 
        volume 
       - Price            21,363 
       - Aggregated        89.4p 
        total 
                           GBP19,098.52 
---  -----------------  ----------------------------------------- 
 f)   Date of            7 July 2017 
       the transaction 
---  -----------------  ----------------------------------------- 
 g)   Place of           London Stock Exchange, AIM 
       the transaction 
---  -----------------  ----------------------------------------- 
 

For further information please contact:

 
 hVIVO plc                            [phone] 
 Kym Denny (Chief Executive 
  Officer) 
 Graham Yeatman (Chief Financial 
  & Business Officer) 
 
 Media Enquiries                      [phone] 
 Susan Flood (Head of Marketing) 
 
 Numis Securities Limited             [phone] 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
 James Black / Michael Burke 
  (Corporate Broking) 
 
 FTI Consulting 
 Simon Conway / Victoria Foster 
  Mitchell (UK)                       [phone] 
 John Capodanno / Evan Smith 
  (US)                                [phone] 
 

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUGUQPMUPMGQM

(END) Dow Jones Newswires

July 10, 2017 02:00 ET (06:00 GMT)